Interés Humano

¿Por qué sigue siendo interesante la dosis de refuerzo anticovid pese a la variante ómicron?

La interrogante actual es hasta qué punto podrá ómicron vulnerar la protección de las vacunas

(FILES) In this file photo taken on May 31, 2021 a nurse prepares a syringe of the Pfizer-BioNtech Covid-19 vaccine at a vaccination centre, in Garlan, western France. - The EU's drug regulator approved Pfizer's coronavirus jab for children aged 5 to 11 on November 25, 2021, clearing the way for the vaccination in a cohort where the virus is rapidly spreading. (Photo by Fred TANNEAU / AFP)
(FILES) In this file photo taken on May 31, 2021 a nurse prepares a syringe of the Pfizer-BioNtech Covid-19 vaccine at a vaccination centre, in Garlan, western France. - The EU's drug regulator approved Pfizer's coronavirus jab for children aged 5 to 11 on November 25, 2021, clearing the way for the vaccination in a cohort where the virus is rapidly spreading. (Photo by Fred TANNEAU / AFP) FRED TANNEAU
‌
‌

‌

‌
‌

‌

‌